SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Openwave Systems (Nasdaq: OPWV) $2.22. Today announced a collaboration arrangement with Amobee Media Systems, the world's largest mobile advertising platform in which the parties intend to develop an end-to-end advertising ecosystem solution for interested mobile operators. Openwave and Amobee intend to create this solution by combining Openwave's Amplicity™ platform and Amobee's carrier-grade mobile advertising platform.
"Mobile operators are looking for better ways to help advertisers understand total mobile user behavior in order to deliver relevant ads to subscribers," said Mark Strecker, COO, Amobee. "We believe that by integrating our mobile ad platform with Openwave's Amplicity platform we can enhance our mobile ad platform and better enable mobile advertisers to effectively deliver advertisements based on a deeper understanding of usage behavior that can ultimately drive the adoption of mobile advertising."
Mobile advertisers benefit from the combination of Openwave's Amplicity platform, which enables contextual data delivery, and Amobee's platform, fostering seamless ad enablement. The joint solution will enable mobile operators to offer advertisements that are more relevant to the subscribers based on subscriber data. In addition, the joint solution will employ a complete end-to-end mobile advertising solution which will include a comprehensive set of mobile media services, enabling advertisers to manage brand building and seamlessly rollout highly-targeted mobile advertising campaigns.
What They Do: Openwave Systems is a global innovator delivering software solutions that enable communication service providers and the broader ecosystem to monetize the growing demand for data services while maximizing their current and future network investments.
BioSante Pharmaceuticals (Nasdaq: BPAX) $2.21. Today announced it has presented critical female sexual dysfunction market data at the ISSWSH (The International Society for the Study of Women’s Sexual Health) annual meeting. The data presented include results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).
There are currently no FDA-approved therapeutic treatment options for women with HSDD. A significant number of physicians (over 90 percent) reported that they prescribe off-label testosterone for women to treat FSD, however, these physicians are dissatisfied with the non-FDA approved, off-label alternatives. The physicians indicated that they hear an average of 37 unsolicited inquiries per month from women regarding sexual dysfunction. Nationally, it is estimated that 4.1 million off-label testosterone prescriptions are filled annually.
What They Do: BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
